Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for treating metabolic disorders and obesity with GIP and GLP-1 receptor-active glucagon-based peptides

A GLP-1, therapeutic agent technology, applied in metabolic diseases, organic active ingredients, pharmaceutical formulations, etc.

Inactive Publication Date: 2013-11-20
MARCADIA BIOTECH
View PDF6 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although GLP-1 therapeutics are associated with weight loss, it is also associated with nausea, which occurs in more than 20% of patients treated with GLP-1 analogs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for treating metabolic disorders and obesity with GIP and GLP-1 receptor-active glucagon-based peptides
  • Methods for treating metabolic disorders and obesity with GIP and GLP-1 receptor-active glucagon-based peptides
  • Methods for treating metabolic disorders and obesity with GIP and GLP-1 receptor-active glucagon-based peptides

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0170] In an exemplary embodiment, the half-life extended GLP-1 / GIP co-agonist peptide of the present disclosure is an analog of native glucagon comprising (i) an amino acid comprising an imidazole side chain at position 1, (ii) A DPP-IV protected amino acid at position 2, (iii) optionally an acylated amino acid or an alkylated amino acid at any of positions 9, 10, 12, 16, 20 or 37-43, wherein an acyl or an alkyl group is optionally (iv) an alpha-helix stabilizing amino acid at one or more of positions 16-21, and (v) up to ten (e.g., up to 2, 3, 4, 5, 6, 7, 8, 9 or 10) other amino acid modifications that retain the desired GIP and GLP-1 activity.

[0171] In any of the exemplary embodiments of this section, the amino acid at position 1 may be His or a derivative of His. In any of the exemplary embodiments, the amino acid at position 2 is an α,α-disubstituted amino acid. In any exemplary embodiment, the α,α-disubstituted amino acid comprises R1 and R2 (each of which is bonded...

Embodiment 1

[0174] Example 1: Half-life extended GLP-1 / GIP co-agonist peptides with an extended half-life of about 5 days are well tolerated

[0175] A phase I, randomized, placebo-controlled, continuous, single-ascending, two-period study in healthy male subjects to assess the safety, tolerability, pharmacokinetics of GLP-1 / GIP co-agonist peptides with extended half-life ( PK) and pharmacodynamic (PD) properties. Select a body mass index of 20 kg / m based on history, physical examination, ECG, and routine laboratory tests (eg, blood, chemistry, blood count, urinalysis, and drug screen) 2 with 30kg / m 2 Healthy adult male subjects (approximately 18 to 55 years of age) were used in the study. The half-life extended GLP-1 / GIP co-agonist peptide tested in all examples was SEQ ID NO:153.

[0176] The subjects were randomly divided into several teams. Cohorts 1, 2, 3, 4, 5, and 6 each consisted of 6 patients receiving 0.1 mg, 0.3 mg, 1 mg, 2 mg, 4 mg, and 8 mg of the half-life-extended GLP-1...

Embodiment 2

[0182] Example 2: GLP-1 / GIP co-agonist peptides with extended half-life increase insulin secretion in a dose-dependent manner

[0183] Phase I, randomized, placebo-controlled, active-controlled two-arm study in healthy male and female subjects to assess the effect of a range of doses on the β-cell response to a glucose load and to assess the effect of these doses on gastric emptying . β-cell function was assessed by calculating prehepatic insulin secretion in response to gradient glucose infusion. Gastric emptying was assessed by measuring the plasma profile of absorbed acetaminophen.

[0184] Subjects in Group 1 (Cohort 1) received two abdominal subcutaneous (SC) injections of placebo 2 hours apart on Day 1, followed by BYETTA (Amylin Pharmaceuticals) two 5 μg abdominal subcutaneous injections (SC). In Arm 2, subjects in Cohort 2 received placebo on day 1, followed by 8 mg of a half-life-extended GLP-1 / GIP co-agonist peptide on day 2. Subjects in Cohort 3 received placebo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

Methods are provided for administering an extended half-life GLP-1 / GIP coagonist peptide to a patient in need thereof for reducing weight gain, inducing weight loss, treating hyperglycemia, reducing blood glucose levels, or normalizing blood glucose levels in said patient.

Description

[0001] priority statement [0002] This application claims priority to US Provisional Application No. 61 / 500,229, filed June 23, 2011, and US Provisional Application No. 61 / 426,338, filed December 22, 2010. [0003] Incorporation by Reference of Electronically Submitted Materials [0004] Incorporated by reference in its entirety is the computer-readable nucleotide / amino acid sequence listing filed concurrently with this application and identifying the sequence listing as follows: a file entitled "45708A_SeqListing.txt" created on December 22, 2011 285,688 byte ASCII (text) file. Background technique [0005] Field of the Disclosure [0006] The present disclosure generally relates to methods of administering half-life-extended GLP-1 / GIP co-agonist peptides. More specifically, the present disclosure relates to methods of reducing weight gain or inducing weight loss via administration of a GLP-1 / GIP co-agonist peptide with an extended half-life, and treating hypertensive dis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/26A61K38/08A61K31/195A61K31/198A61P3/04A61P3/10
CPCA61K31/198A61K38/26A61K31/195A61K45/06A61K38/17A61K47/60A61P1/16A61P3/00A61P3/04A61P3/10A61P43/00A61K2300/00A61K9/0021A61K9/0019
Inventor 路易斯·维格纳提理查德·D·狄马区
Owner MARCADIA BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com